ArticleJournal of oral biology and craniofacial research
ESKAPE pathogens: Emerging isolates in odontogenic orofacial infections.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Odontogenic orofacial infections involve a broad microbial spectrum, with the rise of multidrug-resistant organisms complicating management. ESKAPE pathogens, known for their ability to evade standard antimicrobial therapies, are increasingly implicated in severe infections. However, their prevalence and resistance patterns in odontogenic orofacial space infections remain insufficiently reported. This study aimed to identify the occurrence of ESKAPE pathogens in such infections and assess their antimicrobial susceptibility to guide effective treatment. Methodology: Between August 2019 and June 2022, 132 patients with oral and maxillofacial infections were prospectively enrolled. Pus samples collected using sterile swabs were cultured following standard protocols. Bacterial identification and susceptibility testing were performed using the VITEK 2-Compact system. Results: Twenty-nine samples (21.97%) yielded at least one ESKAPE pathogen, with Enterobacter species being the most common isolate (34.48%). High resistance rates were seen to amoxicillin-clavulanic acid (62.07%), cefuroxime (62.5%) and trimethoprim-sulfamethoxazole (68.42%). Linezolid, ertapenem, and clindamycin demonstrated the highest susceptibility (100%), followed by imipenem (86.96%, p ≤ 0.05). Conclusion: ESKAPE pathogens represent a significant proportion of odontogenic orofacial infections and exhibit considerable resistance to commonly used antibiotics. These findings reinforce the necessity of culture-based therapy and highlight imipenem as a potential option for resistant cases. Strengthened antibiotic stewardship and continued surveillance are essential to manage the growing threat of multidrug-resistant organisms in maxillofacial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.